Carl Domino Inc reduced its stake in shares of Pfizer, Inc. (NYSE:PFE) by 2.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,500 shares of the biopharmaceutical company’s stock after selling 400 shares during the quarter. Carl Domino Inc’s holdings in Pfizer were worth $487,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Fisher Asset Management LLC raised its position in Pfizer by 3.9% during the second quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock valued at $1,143,248,000 after acquiring an additional 1,275,832 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in Pfizer by 1.2% during the first quarter. Schwab Charles Investment Management Inc. now owns 31,260,823 shares of the biopharmaceutical company’s stock valued at $1,069,433,000 after acquiring an additional 377,404 shares in the last quarter. Macquarie Group Ltd. raised its position in Pfizer by 0.9% during the first quarter. Macquarie Group Ltd. now owns 24,683,746 shares of the biopharmaceutical company’s stock valued at $844,431,000 after acquiring an additional 228,405 shares in the last quarter. Boston Partners raised its position in Pfizer by 7.3% during the first quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock valued at $830,071,000 after acquiring an additional 1,649,801 shares in the last quarter. Finally, Bank of Montreal Can raised its position in Pfizer by 1.2% during the second quarter. Bank of Montreal Can now owns 18,534,159 shares of the biopharmaceutical company’s stock valued at $622,562,000 after acquiring an additional 227,682 shares in the last quarter. Institutional investors own 69.00% of the company’s stock.

Several research analysts recently weighed in on the company. Jefferies Group LLC set a $35.00 price target on Pfizer and gave the company a “neutral” rating in a research report on Wednesday, August 2nd. Berenberg Bank set a $39.00 price target on Pfizer and gave the company a “neutral” rating in a research report on Tuesday, August 1st. Morgan Stanley reiterated a “neutral” rating and set a $35.00 price target (down from $38.00) on shares of Pfizer in a research report on Monday, June 12th. Vetr cut Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price target for the company. in a research report on Wednesday, September 13th. Finally, Zacks Investment Research upgraded Pfizer from a “sell” rating to a “hold” rating in a research report on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the company’s stock. Pfizer currently has a consensus rating of “Hold” and a consensus price target of $37.83.

TRADEMARK VIOLATION WARNING: “Carl Domino Inc Sells 400 Shares of Pfizer, Inc. (PFE)” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/09/18/carl-domino-inc-sells-400-shares-of-pfizer-inc-pfe.html.

Shares of Pfizer, Inc. (PFE) traded down 0.06% during mid-day trading on Monday, hitting $35.34. The stock had a trading volume of 4,792,537 shares. The stock has a 50 day moving average price of $33.64 and a 200-day moving average price of $33.53. The company has a market cap of $210.18 billion, a PE ratio of 25.85 and a beta of 1.00. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $35.84.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The firm had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same period last year, the business posted $0.64 EPS. Pfizer’s quarterly revenue was down 1.9% on a year-over-year basis. On average, equities analysts expect that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 1st. Investors of record on Friday, August 4th were paid a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 3.62%. The ex-dividend date of this dividend was Wednesday, August 2nd. Pfizer’s payout ratio is currently 94.12%.

In related news, CEO Ian C. Read sold 96,950 shares of the firm’s stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the transaction, the insider now directly owns 151,474 shares of the company’s stock, valued at $5,074,379. The disclosure for this sale can be found here. Insiders sold a total of 464,521 shares of company stock valued at $15,813,961 over the last ninety days. 0.06% of the stock is currently owned by company insiders.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.